Research Training in Blood Diseases and Resources06/01/2014 - 05/31/2021 (Multi-PI)
PI:
Adam Lerner, MDNIH/National Heart, Lung, and Blood Institute5T32HL007501-36
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma02/03/2014 - 02/02/2021 (PI)
Kyowa Hakko Kirin Pharma, Inc.
A randomized, open-label, phase 3 trial of Brentuximab vedotin (SGN-35) versus physician's choice (Methotrexate or Bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma08/10/2012 - 08/10/2019 (PI)
Millennium Pharmaceuticals, Inc.
PERSONNEL AGREEMENT FOR RESEARCH SERVICES OF DEBORAH GOVAN01/01/2013 - 01/28/2016 (PI)
VA Boston Healthcare System
Research Training in Blood Diseases and Resources09/19/2008 - 05/31/2014 (PI)
NIH/National Heart, Lung, and Blood Institute5T32HL007501-31
Access Program with Denileukin diftitox for the treatment of patients currently receiving treatment with commercially available Ontak11/01/2011 - 10/31/2012 (PI)
Eisai Medical Research Institute, Inc.
A Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients with Metastatic Malignant Melanoma03/27/2006 - 03/26/2008 (PI)
CuraGen Corporation
The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients with Follicular Non-Hodgkin’s Lymphoma11/03/2005 - 11/02/2007 (PI)
Genentech, Inc.
A Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients with Metastatic Malignant Melanoma12/23/2005 - 12/31/2006 (PI)
Luitpold Pharmaceuticals, Inc.
Open-label, Dose Escalation, Followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with06/02/2005 - 06/01/2006 (PI)
Genmab Inc.
Showing 10 of 14 results.
Show All Results
ProMune (CpG 7909 Injection) With or Without Chemotherapy For the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open-Label, Parallel Group, Active-Controlled, Phase II/III Study
02/01/2004 - 01/31/2006 (PI)
Coley Pharmaceutical Group
A Continuation Study of CpG 7909 Injection in Patients with Metastic or Recurrent Malignancies who have Stable Disease or Who Have Responded to CpG 7909 Injection Therapy
02/01/2004 - 01/31/2006 (PI)
Coley Pharmaceutical Group
A Phase II Study Evaluating the Antitumor Activity of MEDI-522 in Patients with Metastatic Melanoma
07/31/2003 - 07/30/2004 (PI)
MedImmune, Inc.
A Pilot Phase I/II Study of Intranodal Delivery of a Plasmid DNA in Stage IV Melanoma Patients
07/03/2002 - 12/03/2003 (PI)
CTL Immuno Therapies Corp.
CRXX-Lerner laboratory CLL Research Collaboration02/01/2008 - 06/30/2011 (PI)
CombinatorX, Inc.
Using audio to convey mind/body approaches to cancer06/14/2006 - 03/31/2011 (PI)
Far Reaching Communications NIHR44 CA86403-02
PDE4 Inhibitors & Glucocorticoids in B-CLL08/01/2006 - 01/31/2011 (PI)
Memory Pharmaceutical Corp.
Mechanistic Studies of BRC3-induced Anti-estrogen Resistance01/01/2010 - 12/31/2010 (PI)
Breast Cancer Alliance
Cell Pathways07/01/2002 - 12/31/2010 (PI)
Cell Pathways Inc
Cyclic AMP - Mediated Apoptosis in Lymphoid Malignancies07/01/2005 - 06/30/2010 (PI)
NIH-NCI5 R01 CA106705-05
Tamoxifen Resistance in Breast Cancer10/31/2002 - 12/31/2009 (PI)
Logica Foundation
Analysis of AND-34 in human breast cancer07/01/2005 - 06/30/2009 (PI)
NIH-NCI5 R01 CA114094-04 (A)
Analysis Of And-3409/01/2001 - 09/30/2005 (PI)
US Army
Apoptosis In Normal And Malign07/01/2000 - 06/30/2005 (PI)
NIH-NCI5 R01 CA79838-04 (A)
Showing 10 of 13 results.
Show All Results
Camp Mediated Apoptosis Human
07/01/1998 - 11/01/2003 (PI)
AS-Clinic Oncology
Phase I Trial For New Anti-Can
02/01/1998 - 01/31/2003 (PI)
Dana Farber Dana Farber
The Role Of And-34
07/01/2000 - 07/01/2001 (PI)
Leukemia Research Fd